NasdaqGS:SNDXBiotechs
Is WODA Revuforj Access Deal Reshaping The Investment Case For Syndax Pharmaceuticals (SNDX)?
On 7 January 2026, the World Orphan Drug Alliance and Syndax Pharmaceuticals announced a collaboration to expand global access to Syndax’s first-in-class menin inhibitor Revuforj (revumenib) via a Managed Access Program for eligible patients outside the U.S. where local regulations and funding allow.
This partnership broadens real-world use of Revuforj in difficult-to-treat KMT2A-rearranged and NPM1-mutated leukemias, potentially strengthening its clinical footprint beyond the U.S. approval...